Surgery is the primary treatment for localized neuroendocrine tumors (NETs). Grade 1-2 NETs traditionally have been considered radioresistant due to their indolent nature but data regarding a role for radiation therapy (RT) are limited to old, small retrospective studies. We performed a retrospective review of patients with grade 1-2 NETs treated with RT at a large academic center to assess response and local failure rates. Radiographic response was evaluated with logistic regression. Local failure was assessed with cumulative incidence rates and competing risk regressions. We identified 35 patients with 78 treated lesions between 1974 and 2017. Most tumors originated from the pancreas (n=13) and bronchus/lung (n=11). Nine (26%) patients had grade 1 tumors, 16 (46%) had grade 2 tumors, and ten (29%) had grade 1-2 tumors. The median biologically effective dose (BED10) was 50.7 Gy (range, 20.0-106.5). The median follow-up was 13.5 months (range, 0.5 to 140.6 months). 20 of 21 (95%) patients had palliation of symptoms. Of 52 intact lesions, response was complete in 7 (13%), partial in 14 (27%), stable in 25 (48%), and progressive in 6 (12%) lesions. Higher BED10 was associated with a response (odds ratio/Gy 1.06; 95% CI, 1.02-1.11; p=0.008). Of 59 intact or resected lesions, the 2-year cumulative incidence of local failure was 26.4%. Grade 2 lesions were associated with local failure (hazard ratio 7.70; 95% CI, 1.22-48.8; p=0.03). We show that grade 1-2 NETs often respond radiographically and symptomatically to RT. RT should be considered in the management of grade 1-2 NETs.

The authors have declared no competing interest.

This study did not receive any funding.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This retrospective study was approved by the Stanford University IRB.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data from this study are not being made publicly available.